The Role of Folic Acid on PC3 Prostate Cancer Cell Line

Year 2024, Volume: 6 Issue: 2, 196 - 200, 16.05.2024

Funda Aydin , Nazmiye Bitgen , Gözde Özge Önder , Munevver Baran

https://doi.org/10.37990/medr.1432649

Abstract

Aim: Prostate cancer (PCa), one of the most common malignant solid tumors, has become a significant and rapidly increasing global health concern for men. One of the vitamins in the B group that is essential in decreasing the risk of cancer is folic acid (FA). However, the protective effects of FA against PCa are insufficiently examined, and the underlying mechanism is still unknown. In this study, androgen-nonresponsive (PC3) human PCa was used to get a better understanding of the effect of FA on cell proliferation.
Material and Method: In the present study, the MTT assay was used to assess FA's inhibitory effect on cellular proliferation. Additionally, all groups underwent the TUNEL immunofluorescence staining procedure to identify apoptosis in the PC3 cell line.
Results: The most appropriate cytotoxic dose was determined to be the 24-hour FA values. When apoptotic TUNEL staining was evaluated in the PC3 cell line, FA significantly increased apoptosis. There was not a significant difference observed between the docetaxel (Dtx) and FA groups in terms of TUNEL-positive cell immunoreactivity in the PC3 cell line. There was no apparent distinction in the immunreactivity intensity of TUNEL-positive cells in these groups.
Conclusion: The present study provides a fresh perspective on the fundamental mechanism underlying FA's capability to prevent PC3 cancer cells from proliferating. Our findings suggest that FA effectively inhibits PC3 cell line proliferation through the upregulation of apoptosis. Consequently, FA may be a potential novel cytotoxic and therapeutic strategy in the treatment of PCa disease.

Keywords

Folic acid, prostate cancer, docetaxel, apoptosis

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359-86.
• Wang Y, Shim MS, Levinson NS, et al. Stimuli-responsive materials for controlled release of theranostic agents. Adv Funct Mater. 2014;24:4206-20.
• Lehto U-S, Tenhola H, Taari K, Aromaa A. Patients’ perceptions of the negative effects following different prostate cancer treatments and the ımpact on psychological well-being: a nationwide survey. Br J Cancer. 2017;116:864-73.
• Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10:63-89.
• Luo D, Wang X, Zeng S, et al. Prostate-specific membrane antigen targeted gold nanoparticles for prostate cancer radiotherapy: Does size matter for targeted particles. Chem Sci. 2019;10:8119-28.
• Anirudhan T, Varghese S, Manjusha V. Hyaluronic acid coated pluronic F127/pluronic P123 mixed micelle for targeted delivery of paclitaxel and curcumin. Int J Biol Macromol. 2021;192:950-7.
• Pieroth R, Paver S, Day S, Lammersfeld C. Folate and its impact on cancer risk. Curr Nutr Rep. 2018;7:70-84.
• Friso S, Choi S-W. Gene-nutrient interactions and DNA methylation. J Nutr. 2002;132:2382S-7.
• Cheng W, Nie J, Xu Lv, et al. pH-sensitive delivery vehicle based on folic acid-conjugated polydopamine-modified mesoporous silica nanoparticles for targeted cancer therapy. ACS Appl Mater Interfaces. 2017;9:18462-73.
• Yao V, Berkman CE, Choi JK, et al. Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid. Prostate. 2010;70:305-16.
• Stolzenberg-Solomon RZ, Chang S-C, Leitzmann MF, et al. Folate intake, alcohol use, and postmenopausal breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Clin Nutr. 2006;83:895-904.
• Rivero-Buceta E, Vidaurre-Agut C, Vera-Donoso CD, et al. PSMA-Targeted mesoporous silica nanoparticles for selective intracellular delivery of docetaxel in prostate cancer cells. ACS Omega. 2019;4:1281-91.
• Katsumata N. Docetaxel: an alternative taxane in ovarian cancer. Br J Cancer. 2003;89:S9-15.
• Önder GÖ, Goktepe Ö, Baran M, et al. Therapeutic potential of hesperidin: Apoptosis induction in breast cancer cell lines. Food Chem Toxicol. 2023;176:113791.
• Genc S, Pennisi M, Yeni Y, et al. Potential neurotoxic effects of glioblastoma-derived exosomes in primary cultures of cerebellar neurons via oxidant stress and glutathione depletion. Antioxidants (Basel). 2022;11:1225.
• Baran M, Onder GO, Goktepe O, Yay A. Role of apoptosis and autophagy in folic acid-induced cytotoxicity of human breast cancer cells in vitro. Fundam Clin Pharmacol. 2024;38:126-38.
• Hwang SY, Kang YJ, Sung B, et al. Folic acid is necessary forproliferation and differentiation of C2C12 myoblasts. J Cell Physiol. 2018;233:736-47.
• Rycyna KJ, Bacich DJ, O'Keefe DS. Opposing roles of folate in prostate cancer. Urology. 2013;82:1197-203.
• Yegnasubramanian S, Haffner MC, Zhang Y, et al. DNA hypomethylation arises later in prostate cancer progression than Cp Gisland hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res. 2008;68:8954-67.
• Craenen K, Verslegers M, Baatout S, Abderrafi Benotmane M. An appraisal of folates as key factors in cognition and ageing-related diseases. Crit Rev Food Sci Nutr. 2020;60:722-39.
• Hassn Mesrati M, Syafruddin SE, Mohtar MA, Syahir A. CD44: a multifunctional mediator of cancer progression. Biomolecules. 2021;11:1850.
• Purohit B, Kumar A, Mahato K, et al. Cancer cytosensing approaches in miniaturized settings based on advanced nanomaterials and biosensors. In: Nanotechnology in modern animal biotechnology. Elsevier. 2019;133-47.
• Song H, Su C, Cui W, et al. Folic acid-chitosan conjugated nanoparticles for improving tumor-targeted drug delivery. BioMed Res Int. 2013;2013:723158.
• Scaranti M, Cojocaru E, Banerjee S, Banerji U. Exploiting the folate receptor Α in oncology. Nat Rev Clin Oncol. 2020;17:349-59.
• Omote S, Takata K, Tanaka T, et al. Over expression of folate receptor alpha is an inde- pendent prognostic factor for outcomes of pancreatic cancer patients. Med Mol Morphol. 2018;51:237-43.
• Richmond RC, Sharp GC, Herbert G, et al. The long-term impact of folic acid in pregnancy on offspring DNA methylation: follow-up of the aberdeen folic acid supplementation trial (AFAST). Int J Epidemiol. 2018;47:928-37.
• Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35:495-516.
• Bonvin D, Bastiaansen JA, Stuber M, et al. Folic acid on iron oxide nanoparticles: platform with high potential for simultaneous targeting, MRI detection and hyperthermia treatment of lymph node metastases of prostate cancer. Dalton Trans. 2017;46:12692-704.
• Manshadi SD, Ishiguro L, Sohn K-J, et al. Folic acid supplementation promotes mammary tumor progression in a rat model. PLoS One 2014;9:e84635.
• Kayani Z, Bordbar AK, Firuzi O. Novel folic acid-conjugated doxo-rubicin loadedβ-lactoglobulin nanoparticles induce apoptosis inbreast cancer cells. Biomed Pharmacother. 2018;107:945-56.
• He C, Heidari Majd M, Shiri F, Shahraki S. Palladium and platinum complexes of folic acid as new drug delivery systems for treatment of breast cancer cells. J Mol Struct. 2021;1229:129806.
• Popgeorgiev N, Sa JD, Jabbour L, et al. Ancient and conserved functional interplay between Bcl-2 family proteins in the mitochondrial pathway of apoptosis. Sci Adv. 2020;6:eabc4149.
• Xiao SD, Meng XJ, Shi Y, et al. Interventional study of high dose folic acid in gastric carcinogenesis in beagles. Gut. 2002;50:61-4.